• Products
  • Suppliers
  • Sourcing Requests
Post Sourcing Request Exhibition
Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!
Note: You can unsubscribe from the alerts at any time.
Advertising
New Products
Gelatin, Soft Capsule Gelatin, Hard Capsule Gelatin, Pharmaceutical Gelatin-Foodmate
Neohesperidin
Advantame
Cleanroom Bench Horizontal Laminar Flow Hood Airflow Clean Bench
Pharma and Food Grade, USP/FCC Neotame Sweetener E961
Trilobatin

Oncology biotech Tyra Biosciences files for a $100 million IPO

firstwordpharmaAugust 23, 2021

Tag: Tyra , FGFR , IPO

Tyra Biosciences, which is developing FGFR inhibitors for cancer, filed plans with the SEC to raise up to $100 million in an initial public offering, as reported in Renaissance Capital.

The company is using its proprietary SNÅP platform to generate next-generation candidates that are specifically designed to address acquired drug resistance and provide alternative treatment options.

Its lead candidate, TYRA-300, is designed to selectively inhibit FGFR3, with an initial focus on patients with bladder cancer.

Tyra anticipates filing an investigational new drug application for TYRA-300 in mid-2022.


Previous:South Korea to get more Moderna COVID shots in boost to vaccination effort

Next:UK scientists look at reducing boosters to save vaccine for rest of the world

Related News

Everest Medicines Announces Acceptance of the New Drug Application for VELSIPITY

Everest Medicines LimitedDecember 20, 2024

Everest Medicines announced NMPA acceptance of NDA for VELSIPITY(R) (etrasimod) to treat moderately to severely active UC.

Manulife Hong Kong Partners with New Frontier Group to Enhance Cross-Border Healthcare Services

PRNewswireDecember 12, 2024

Menarini Group and MEDSIR Present the Phase III Study ADELA: A New Therapeutic Strategy for Advanced Breast Cancer

PRNewswireDecember 12, 2024

Oncology biotech Tyra Biosciences files for a $100 million IPO | Pharmasources.com

Core8 Group and MedArmor to Pioneer Vietnam's First AI x ESG Hospital

PRNewswireDecember 12, 2024

Core8 Group, an Australian leader in high-tech and biotech innovation, has unveiled plans to develop Vietnam's first AI x ESG Hospital, marking a significant milestone in healthcare transformation.

You may like
More>>

Sodium tripolyphosphate

Sodium tripolyphosphate
3-Hydroxybutyrate Calcium

3-Hydroxybutyrate Calcium
Teniposide

Teniposide
Dipotassium Hydrogenphosphate

Dipotassium Hydrogenphosphate
Alpha lipoic acid

Alpha lipoic acid
Alpha Lipoic Acid / ALA 1077-28-7

Alpha Lipoic Acid / ALA 1077-28-7
Buffering Agent Tripotassium Phosphate (TKP) K3po4 with High Purity

Buffering Agent Tripotassium Phosphate (TKP) K3po4 with High Purity
Calcipotriene

Calcipotriene
Calcipotriol

Calcipotriol
Calcium beta-hydroxy-beta-methylbutyrate (HMB-Ca)

Calcium beta-hydroxy-beta-methylbutyrate (HMB-Ca)

Contact Us

PharmaSources@imsinoexpo.com

Tel: (+86) 400 610 1188

WhatsApp/Telegram/Wechat: +86 13621645194

About Us
About PharmaSources
Terms of Service
Privacy Policy
Intellectual Property
Media Partners
Buy
Search Products
Post Sourcing Requests
Search Suppliers
CAS Search
Sell
Member Application
Advertising
Post Products
EZSourcing
Events
CPHI China
PMEC China
Conferences
Search Events
Help
FAQ
Contact Us
Feedback
PharmaSources Customer Service